Gastric Motility Disorder Drug Market Report

Global Gastric Motility Disorder Drug Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：164
  • REPORT CODE：GMM862864
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Gastric Motility Disorder Drug market report explains the definition, types, applications, major countries, and major players of the Gastric Motility Disorder Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Concert Pharmaceuticals Inc

    • Helsinn Healthcare SA

    • ChironWells GmbH

    • Theravance Inc

    • Targacept Inc

    By Type:

    • Velusetrag

    • Ipamorelin

    • TD-8954

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Home Use

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENTS:

    • 1. Global Gastric Motility Disorder Drug Executive Summary

    • 2 Coronavirus Impact

    • 3 Strategic Analytics to Boost Productivity and Profitability

    • 4 Key Inferences

    • 5 Market Overview

    • 6 Global Gastric Motility Disorder Drug Market- Recent Developments

    • 7 Gastric Motility Disorder Drug Raw Materials and Cost Structure Analysis

    • 8 Global Gastric Motility Disorder Drug Import and Export Analysis (Top 10 Countries)

    • 9 Global Gastric Motility Disorder Drug Market Outlook by Types and Applications to 2022

    • 10 Region and Country-wise Gastric Motility Disorder Drug Market Analysis and Outlook till 2022

    • 11 Global Gastric Motility Disorder Drug Competitive Analysis

    • 12 Global Gastric Motility Disorder Drug Market Outlook by Types and Applications to 2028

    • 13 Country-wise Gastric Motility Disorder Drug Market Analysis and Outlook to 2028

    • 14 Conclusions

    • The List of Tables and Figures

    TABLE OF CONTENT

    1. Global Gastric Motility Disorder Drug Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Gastric Motility Disorder Drug Outlook to 2028- Original Forecasts

    • 2.2 Gastric Motility Disorder Drug Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Gastric Motility Disorder Drug Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Gastric Motility Disorder Drug Market- Recent Developments

    • 6.1 Gastric Motility Disorder Drug Market News and Developments

    • 6.2 Gastric Motility Disorder Drug Market Deals Landscape

    7 Gastric Motility Disorder Drug Raw Materials and Cost Structure Analysis

    • 7.1 Gastric Motility Disorder Drug Key Raw Materials

    • 7.2 Gastric Motility Disorder Drug Price Trend of Key Raw Materials

    • 7.3 Gastric Motility Disorder Drug Key Suppliers of Raw Materials

    • 7.4 Gastric Motility Disorder Drug Market Concentration Rate of Raw Materials

    • 7.5 Gastric Motility Disorder Drug Cost Structure Analysis

      • 7.5.1 Gastric Motility Disorder Drug Raw Materials Analysis

      • 7.5.2 Gastric Motility Disorder Drug Labor Cost Analysis

      • 7.5.3 Gastric Motility Disorder Drug Manufacturing Expenses Analysis

    8 Global Gastric Motility Disorder Drug Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Gastric Motility Disorder Drug Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Gastric Motility Disorder Drug Export by Region (Top 10 Countries) (2017-2028)

    9 Global Gastric Motility Disorder Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Gastric Motility Disorder Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Velusetrag Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Ipamorelin Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global TD-8954 Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Gastric Motility Disorder Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Home Use Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Gastric Motility Disorder Drug Market Analysis and Outlook till 2022

    • 10.1 Global Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.2.2 Canada Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.2.3 Mexico Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.2 UK Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.3 Spain Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.4 Belgium Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.5 France Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.6 Italy Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.7 Denmark Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.8 Finland Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.9 Norway Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.10 Sweden Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.11 Poland Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.12 Russia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.3.13 Turkey Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.2 Japan Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.3 India Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.4 South Korea Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.5 Pakistan Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.6 Bangladesh Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.7 Indonesia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.8 Thailand Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.9 Singapore Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.10 Malaysia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.11 Philippines Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.4.12 Vietnam Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.2 Colombia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.3 Chile Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.4 Argentina Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.5 Venezuela Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.6 Peru Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.7 Puerto Rico Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.5.8 Ecuador Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.6.2 Kuwait Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.6.3 Oman Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.6.4 Qatar Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.7.2 South Africa Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.7.3 Egypt Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.7.4 Algeria Gastric Motility Disorder Drug Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Gastric Motility Disorder Drug Consumption (2017-2022)

      • 10.8.2 New Zealand Gastric Motility Disorder Drug Consumption (2017-2022)

    11 Global Gastric Motility Disorder Drug Competitive Analysis

    • 11.1 Concert Pharmaceuticals Inc

      • 11.1.1 Concert Pharmaceuticals Inc Company Details

      • 11.1.2 Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Main Business and Markets Served

      • 11.1.4 Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Helsinn Healthcare SA

      • 11.2.1 Helsinn Healthcare SA Company Details

      • 11.2.2 Helsinn Healthcare SA Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Helsinn Healthcare SA Gastric Motility Disorder Drug Main Business and Markets Served

      • 11.2.4 Helsinn Healthcare SA Gastric Motility Disorder Drug Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 ChironWells GmbH

      • 11.3.1 ChironWells GmbH Company Details

      • 11.3.2 ChironWells GmbH Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 ChironWells GmbH Gastric Motility Disorder Drug Main Business and Markets Served

      • 11.3.4 ChironWells GmbH Gastric Motility Disorder Drug Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Theravance Inc

      • 11.4.1 Theravance Inc Company Details

      • 11.4.2 Theravance Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Theravance Inc Gastric Motility Disorder Drug Main Business and Markets Served

      • 11.4.4 Theravance Inc Gastric Motility Disorder Drug Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Targacept Inc

      • 11.5.1 Targacept Inc Company Details

      • 11.5.2 Targacept Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Targacept Inc Gastric Motility Disorder Drug Main Business and Markets Served

      • 11.5.4 Targacept Inc Gastric Motility Disorder Drug Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Gastric Motility Disorder Drug Market Outlook by Types and Applications to 2028

    • 12.1 Global Gastric Motility Disorder Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Velusetrag Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Ipamorelin Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global TD-8954 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Gastric Motility Disorder Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Home Use Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Gastric Motility Disorder Drug Market Analysis and Outlook to 2028

    • 13.1 Global Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.2.2 Canada Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.2 UK Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.3 Spain Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.5 France Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.6 Italy Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.8 Finland Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.9 Norway Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.11 Poland Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.12 Russia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.2 Japan Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.3 India Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.3 Chile Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.6 Peru Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.6.3 Oman Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Gastric Motility Disorder Drug Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Gastric Motility Disorder Drug

    • Figure of Gastric Motility Disorder Drug Picture

    • Table Global Gastric Motility Disorder Drug Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Gastric Motility Disorder Drug Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Velusetrag Consumption and Growth Rate (2017-2022)

    • Figure Global Ipamorelin Consumption and Growth Rate (2017-2022)

    • Figure Global TD-8954 Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Home Use Consumption and Growth Rate (2017-2022)

    • Figure Global Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Table North America Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure United States Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Canada Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Mexico Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure Germany Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure UK Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Spain Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Belgium Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure France Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Italy Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Denmark Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Finland Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Norway Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Sweden Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Poland Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Russia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Turkey Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table APAC Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure China Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure India Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Thailand Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Singapore Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Philippines Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table South America Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure Brazil Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Colombia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Chile Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Argentina Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Peru Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table GCC Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure Bahrain Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Oman Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Qatar Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table Africa Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure Nigeria Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure South Africa Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Egypt Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure Algeria Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table Oceania Gastric Motility Disorder Drug Consumption by Country (2017-2022)

    • Figure Australia Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Gastric Motility Disorder Drug Consumption and Growth Rate (2017-2022)

    • Table Concert Pharmaceuticals Inc Company Details

    • Table Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Main Business and Markets Served

    • Table Concert Pharmaceuticals Inc Gastric Motility Disorder Drug Product Portfolio

    • Table Helsinn Healthcare SA Company Details

    • Table Helsinn Healthcare SA Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Helsinn Healthcare SA Gastric Motility Disorder Drug Main Business and Markets Served

    • Table Helsinn Healthcare SA Gastric Motility Disorder Drug Product Portfolio

    • Table ChironWells GmbH Company Details

    • Table ChironWells GmbH Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table ChironWells GmbH Gastric Motility Disorder Drug Main Business and Markets Served

    • Table ChironWells GmbH Gastric Motility Disorder Drug Product Portfolio

    • Table Theravance Inc Company Details

    • Table Theravance Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Theravance Inc Gastric Motility Disorder Drug Main Business and Markets Served

    • Table Theravance Inc Gastric Motility Disorder Drug Product Portfolio

    • Table Targacept Inc Company Details

    • Table Targacept Inc Gastric Motility Disorder Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Targacept Inc Gastric Motility Disorder Drug Main Business and Markets Served

    • Table Targacept Inc Gastric Motility Disorder Drug Product Portfolio

    • Figure Global Velusetrag Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ipamorelin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global TD-8954 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Home Use Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Table North America Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure Germany Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure China Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure Brazil Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Gastric Motility Disorder Drug Consumption Forecast by Country (2022-2028)

    • Figure Australia Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Gastric Motility Disorder Drug Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US